

Drug Name	Tumour Group	Regimen Name on NCCP website	Regimen Number	
5-Fluorouracil	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378	
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377	
		Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
	5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)- Continuous infusion 7 day		421	
	Aflibercept-14 days		238	
	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day		446	
	Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days		449	
	CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen		460	
	epiRUBicin, CISplatin and 5-FU (ECF) Therapy		240	
	epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day		429	
	FLOT Therapy-14 day		344	
	FLOX Therapy		486	
	FOLFIRI (14 days)+ Cetuximab (14 days) Therapy		585	
	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy		328	
	FOLFIRI Therapy-14 day		227	
	FOLFIRINOX Therapy		329	
	FOLFOX-4 Therapy-14 day		210	
	FOLFOXIRI Therapy		555	
	Modified FOLFIRINOX Therapy		515	
	Modified FOLFOX-6 Chemoradiation Therapy-14 day		509	
	Modified FOLFOX-6 Therapy-14 day		209	
	Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen		427	
	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day		448	
	Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day		447	
	QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly		428	
	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days		502	
	CISplatin, Infusional 5-Fluorouracil and Radiation Therapy		594	
	5-Fluorouracil and Folinic Acid Therapy-14 day		660	
	Genitourinary		5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
	Head & Neck		CARBOplatini (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle	552
			Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
			Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle	417
			CISplatin and 5-Fluorouracil Therapy-28 day	314
			DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324

5-Fluorouracil	Head & Neck	DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315	
		CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radioi	589	
		CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiother	591	
Abiraterone	Genitourinary	Abiraterone 1000mg and Prednisolone 5mg Therapy	577	
		Abiraterone and Prednisolone Therapy	103	
Acalabrutinib	Leukaemia	Acalabrutinib Monotherapy	656	
Afatinib	Lung	Afatinib Monotherapy	221	
Aflibercept	Gastrointestinal	Aflibercept-14 days	238	
Alectinib	Lung	Alectinib Monotherapy	401	
Alemtuzumab	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611	
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-	638	
Anastrozole	Breast	Anastrozole Monotherapy	254	
Apalutamide	Genitourinary	Apalutamide therapy	574	
Arsenic trioxide	Leukaemia/BMT	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357	
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356	
Atezolizumab	Genitourinary	Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
	Lung	Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
Avelumab	Skin/Melanoma	Avelumab Monotherapy	535	
Axitinib	Genitourinary	Axitinib Monotherapy	104	
		Pembrolizumab 200mg and Axitinib Therapy	583	
Azacitidine	Leukaemia/BMT	Azacitidine 100mg/m2 5-day Therapy	288	
		Azacitidine 75mg/m2 5-2-2 Therapy	287	
Bendamustine	Leukaemia/BMT	Bendamustine Monotherapy	527	
		Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529
			Obinutuzumab and Bendamustine Therapy-28 day cycle	424
			riTUXimab and Bendamustine Therapy	345
Bevacizumab	Breast	Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
	Gastrointestinal	Bevacizamab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
		Bevacizumab 5mg/kg - 14 days	211	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		Bevacizumab 7.5mg/kg-21days	214	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 2	623	
		Genitourinary	Bevacizumab 10mg/kg-14days	212
	Gynaecology	Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175r	620	
	Lung	Bevacizumab 15mg/kg - 21 days	215	
		Bevacizumab 7.5mg/kg-21days	214	
(blank)	Bevacizumab 7.5mg/kg-21days	214		
Bicalutamide	Genitourinary	Bicalutamide Therapy	482	
binimetinib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563	
Bleomycin	Genitourinary	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		Lymphoma	ABVD Therapy	290

Bleomycin	Lymphoma	Escalated Dose BEACOPP 21 day Therapy	354
Blinatumomab	Leukaemia/BMT	Blinatumomab Therapy	538
	Paediatric Oncology	Blinatumomab Paediatric Therapy	P00567
Bortezomib	Myeloma	Bortezomib , Melphalan and Prednisolone	275
		Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
		Bortezomib and Dexamethasone Therapy	270
		Bortezomib Maintenance Therapy- 14 day	435
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Modified CyBorD/ Bortezomib, Cyclophosphamide and Dexamethasone –Weekly Therapy	299
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21	273
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 2	643
Bortezomib	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560
		Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Ther	609
Bosutinib	Leukaemia/BMT	Bosutinib Monotherapy	224
Brentuximab vedotin	Leukaemia/BMT	Brentuximab vedotin Monotherapy	234
	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529
		Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530
		Brentuximab vedotin Monotherapy	234
		Brentuximab vedotin and ICE Therapy	528
Brigatinib	Lung	Brigatinib Therapy	562
Busulfan	Transplant	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched	662
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched	663
Cabazitaxel	Genitourinary	Cabazitaxel and Prednisolone	101
Cabozantanib	Genitourinary	Cabozantanib Therapy	518
Capecitabine	Breast	Capecitabine Monotherapy	216
		Lapatinib and Capecitabine	217
	Gastrointestinal	Capecitabine 825mg/m2 and RT–7 day	586
		Capecitabine and RT – 7 day	523
		Capecitabine and Temozolomide Therapy*	505
		Capecitabine Monotherapy	216
		Capecitabine/Oxaliplatin (XELOX) Therapy	321
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524
		Gemcitabine + Capecitabine Therapy	384
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 2	623
CARBOplatin	Breast	CARBOplatin (AUC4-6) Monotherapy-21 days	261
		CARBOplatin (AUC4-6) Monotherapy-28 days	251
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		DOCetaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
		Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430

CARBOplatin	Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422	
	Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
	Gynaecology	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419	
		CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308	
		CARBOplatin (AUC4-6) Monotherapy-21 days	261	
		CARBOplatin (AUC4-6) Monotherapy-28 days	251	
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175r	620	
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/r	624	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	676	
		Head & Neck	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419
			CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days	332
	CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle		552	
	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle		418	
	CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy		589	
	CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy		591	
	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561	
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271	
		CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304	
		CARBOplatin and Oral Etoposide Therapy-21 days	319	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579	
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568	
		PEMEtrexed and CARBOplatin Therapy	318	
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy		309		
CARBOplatin and vinORElbine Therapy-21 Day		614		
Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397		
	Brentuximab vedotin and ICE Therapy	528		
carfilzomib	Myeloma	Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598	
carfilzomib		Carfilzomib and Dexamethasone (Kd) Therapy - 28 day	566	
Carmustine	Transplant	Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamet	405	
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-	638	
Carmustine (BCNU)	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408	
Ceritinib	Lung	Ceritinib Monotherapy	340	
Cetuximab	Gastrointestinal	Cetuximab (14 days) and Irinotecan (14 days) Therapy	331	
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330	
		Cetuximab Monotherapy-7 days	207	
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585	

Cetuximab	Gastrointestinal	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328	
		Head & Neck	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
	Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle		417	
	Cetuximab Monotherapy-7 days		207	
Chlorambucil	Leukaemia/BMT	Chlorambucil10mg/m2 Therapy	411	
		Obinutuzumab and Chlorambucil Therapy	286	
	Lymphoma	Chlorambucil10mg/m2 Therapy	411	
CISplatin	Gastrointestinal	CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen	460	
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473	
		CISplatin and Teysono-28 day cycle	235	
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day	383	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
		Genitourinary	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
			CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
			CISplatin, Methotrexate and Vinblastine Therapy	337
			Etoposide and CISplatin 20mg/m2 (EP) Therapy	301
			Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day	282
	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy		333	
	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days		338	
	Gemcitabine (1000mg/m2) and CISplatin (35mg/m2) Therapy- 2		622	
	Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 2		628	
	Gynaecology		CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
		Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (A	676	
		Head & Neck	Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle	417
			CISplatin (100mg/m2) with Radiotherapy (RT)	387
	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)		385	
	CISplatin and 5-Fluorouracil Therapy-28 day		314	
	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy		324	
	DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy		323	
	Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day		517	
	Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery		315	
	Cyclophosphamide, Doxorubicin and Displatin Therapy - 21 Day		615	
	Lung		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456

CISplatin	Lung	CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day	279
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy-21 day	281
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
		PEMEtrexed and CISplatin Therapy	317
		Vinorelbine and CISplatin Therapy-21 days	339
		Vinorelbine and CISplatin Therapy-28 days	343
		Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy
	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle		420
	Lymphoma	(R**)-DHAP Therapy	395
Brentuximab vedotin and ESHAP therapy (BRESHAP)		530	
(R*)- ESHAP Therapy		394	
	riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-Gl	441	
Cladribine	Leukaemia/BMT	Cladribine 0.14mg/kg Day 1 to 5 Therapy	402
		Cladribine 0.14mg/kg Weekly Therapy	469
	Leukaemia/BMT,	Cladribine 5 day and riTUXimab Therapy	531
		Cladribine Weekly and riTUXimab Therapy	534
Cobimetinib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
Crizotinib	Lung	Crizotinib Monotherapy	243
Cyclophosphamide	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263

Cyclophosphamid	Breast	epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262	
	Gynaecology	EMA/CO Therapy	248	
	Head & Neck	Cyclophosphamide, Doxorubicin and Displatin Therapy - 21 Day	615	
	Leukaemia/BMT		Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241
		Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISStine and Prednisolone (*R)-CHOP Therapy– 14 days	409
	(*riTUXimab), Cyclophosphamide VinCRISStine and Prednisolone (*R)-CVP) Therapy– 21 days		293	
	(R*)-CHOP – 21 days		307	
	(R**) - miniCHOP Therapy – 21 days		436	
	CHOEP Therapy– 21 days		396	
	Dose Adjusted R-EPOCH Therapy		355	
	Escalated Dose BEACOPP 21 day Therapy		354	
	Nordic Therapy		393	
	Obinutuzumab and CHOP Therapy – 21 day		549	
	obinutuzumab and CVP therapy -21 days		550	
	R-CEOP Therapy – 21 days		510	
	R-CODOX-M Therapy (Patients greater than 65 years)		403	
	R-CODOX-M Therapy (Patients less than or equal to 65 years)		398	
	riTUXimab-HyperCVAD Therapy (MCL) – Part A		466	
	Cyclophosphamide, DOXOrubicin, vinCRISStine and prednisoLONE (riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISStine and		307.1	
	Dose Adjusted R (S/C)-EPOCH Therapy	672		
	Myeloma	Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299	
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21	273	
	Lymphoma and M	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438	
	CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenle	606	
		Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenle	607	
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatchche	629	
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatchche	630	
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631	
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637	
		Busulfan/Cyclophosphamide MAC-MUD	639	
		Busulfan/Cyclophosphamide MAC-SIB	641	
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched	662	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched		663		
Cyclophosphamid e - Oral	Breast	Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377	
		Leukaemia/BMT	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410
	Lymphoma	Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532	
Cytarabine	Leukaemia/BMT	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360	
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359	
		FLAG:Ida 8mg/m2 Therapy	362	
		High Dose Cytarabine Therapy	365	
		Intermediate Dose Cytarabine Therapy	364	
		Gemtuzumab ozogamicin in combination with DAUNOrubicin anc	612	
	Lymphoma	(R**) -DHAP Therapy	395	
		BEAM Autologous Transplant Conditioning Protocol	408	
	Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530		

Cytarabine	Lymphoma	High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRix) therapy	508
		LEAM Autologous Transplant Conditioning Protocol	468
		Nordic Therapy	393
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		ritUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper (R*)- ESHAP Therapy	467
	Leukaemia	FLAG Therapy	363
Transplant	Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682	
	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-	638	
Dabrafenib	Skin/Melanoma	Dabrafenib Monotherapy	237
		Trametinib and Dabrafenib Therapy	415
Dacarbazine	Sarcoma	Dacarbazine (1.2 g/m2) Therapy – 21 day	511
	Skin/Melanoma	Dacarbazine Therapy	464
	Lymphoma	ABVD Therapy	290
Dacomitinib	Lung	Dacomitinib Monotherapy	565
DACTINomycin	Gynaecology	DACTINomycin Therapy	247
		EMA/CO Therapy	248
		Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264
Daratumumab	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560
Daratumumab	Myeloma	Daratumumab Monotherapy	426
Daratumumab SC	Myeloma	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Th	609
		Daratumumab SC Monotherapy	604
Daunorubicin	Leukaemia/BMT	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		Gemtuzumab ozogamicin in combination with DAUNOrubicin anc	612
	Leukaemia	Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
Decitabine	Leukaemia/BMT	Decitabine Monotherapy – AML (28 day cycle)	231
Degarelix	Genitourinary	Degarelix Therapy- 28 day	481
Dinutuximab beta	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
DOCEtaxel	Breast	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250
		DOCEtaxel Monotherapy 100mg/m2 – 21 day cycle	202
		DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
		DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle	423
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
	Gastrointestinal	FLOT Therapy-14 day	344
		DOCEtaxel 75mg/m2 - Prednisolone combination therapy	546
	Genitourinary	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
		DOCEtaxel Monotherapy 50mg/m2 Monotherapy-14 day	313
		DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
	Gynaecology	DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
		DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy (Induction) Therapy	324
	Head & Neck	DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation	323
		Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315
		DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle	203
	Lung	Nindetanib Therapy	372
		Gemcitabine and DOCEtaxel Therapyi - 21 day	501
Sarcoma			

DOXOrubicin	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle	423
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		Gastrointestinal	DOXOrubicin (60mg/m2) Therapy
	Genitourinary	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Head & Neck	Cyclophosphamide, Doxorubicin and Displatin Therapy - 21 Day	615
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
		DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420
		DOXOrubicin (60) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
	Lymphoma	DOXOrubicin 75mg/m2 Monotherapy	500
		(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(R*)-CHOP – 21 days	307
(R**)- miniCHOP Therapy – 21 days		436	
ABVD Therapy		290	
CHOEP Therapy– 21 days		396	
Dose Adjusted R-EPOCH Therapy		355	
Escalated Dose BEACOPP 21 day Therapy		354	
Nordic Therapy		393	
Obinutuzumab and CHOP Therapy – 21 day		549	
R-CODOX-M Therapy (Patients greater than 65 years)		403	
R-CODOX-M Therapy (Patients less than or equal to 65 years)		398	
riTUXimab-HyperCVAD Therapy (MCL) – Part A		466	
Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine anc		307.1	
Dose Adjusted R (S/C)-EPOCH Therapy		672	
Durvalumab	Lung	Durvalumab 10mg/kg Monotherapy-14 Day	576
		Durvalumab 1500mg Monotherapy-28 Day	655
Encorafenib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563

Enzalutamide	Genitourinary	Enzalutamide Monotherapy	233
epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
	Gastrointestinal	epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239
Eribulin	Breast	EriBULLin Monotherapy	228
Erlotinib	Lung	Erlotinib Monotherapy	219
Etoposide	Genitourinary	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
		CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Gynaecology	EMA/CO Therapy	248
		Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		Two Day Etoposide CISplatin (EP) Therapy	267
	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456
		CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day	279
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		BEAM Autologous Transplant Conditioning Protocol	408
		Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		LEAM Autologous Transplant Conditioning Protocol	468
		R-CEOP Therapy – 21 days	510
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		SMILE Therapy (NK or T-cell lymphoma)	407
		(R*)- ESHAP Therapy	394
Brentuximab vedotin and ICE Therapy		528	
Dose Adjusted R (S/C)-EPOCH Therapy	672		
Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-	638	
Etoposide Oral	Lung	CARBOplatin and Oral Etoposide Therapy-21 days	319
		Oral Etoposide Therapy	388
	Lymphoma	R-CEOP Therapy – 21 days	510
Everolimus	Breast	Everolimus and Exemestane Therapy	322
	Genitourinary	Everolimus Monotherapy	320
	Neuroendocrine	Everolimus Monotherapy	320

Exemestane	Breast	Everolimus and Exemestane Therapy	322
		Exemestane Monotherapy	376
Fludarabine	Leukaemia/BMT	FLAG:Ida 8mg/m2 Therapy	362
		Fludarabine, Cyclophosphamide and ritUXimab (FC IV+R) Therapy	241
		Fludarabine, Cyclophosphamide and ritUXimab (FC Oral+R) Therapy	410
	Leukaemia	FLAG Therapy	363
	CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenle	606
		Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenle	607
	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
Folinic Acid	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		FLOT Therapy-14 day	344
		FLOX Therapy	486
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOX-4 Therapy-14 day	210
		FOLFOXIRI Therapy	555
		Modified FOLFIRINOX Therapy	515
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509
		Modified FOLFOX-6 Therapy-14 day	209
		Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 5	427
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428
		5-Fluorouracil and Folinic Acid Therapy-14 day	660
	Lymphoma	R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		SMILE Therapy (NK or T-cell lymphoma)	407
	Fulvestrant	Breast	Fulvestrant Therapy
Gefitinib	Lung	Gefitinib Monotherapy	220
Gemcitabine	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524
	Gastrointestinal	Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy-21 day	383
		Gemcitabine (1000mg/m2) and RT therapy	521
		Gemcitabine (1000mg/m2) Monotherapy - 28 day	284
		Gemcitabine (1000mg/m2) Monotherapy - 56 day	283
		Gemcitabine (400mg/m2) and RT therapy	522
		Gemcitabine (600mg/m2) and RT therapy	559
		Gemcitabine + Capecitabine Therapy	384
		Nab-PAClitaxel (Abraxane®) and Gemcitabine – 28 day	256
		Genitourinary	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy-21 day
	Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy-28 day		282

Gemcitabine	Genitourinary	Gemcitabine (1000mg/m ²) and CISplatin (35mg/m ²) Therapy- 2	622
		Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) Therapy- 2	628
	Gynaecology	Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 4) Therapy- 21 day	306
		Gemcitabine (1000mg/m ²), CARBOplatin (AUC 4) and Bevacizumab Therapy - 21 day	499
	Head & Neck	Gemcitabine (1250mg/m ²) and CISplatin (80mg/m ²) Therapy - 21 day	517
		Gemcitabine (1250mg/m ²) Monotherapy - 21 day	514
	Lung	Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Gemcitabine (1000mg/m ²) Monotherapy - 28 day	284
		Gemcitabine (1250mg/m ²) and CISplatin (75mg/m ²) Therapy- 21 day	281
	Sarcoma	Gemcitabine and DOCEtaxel Therapy - 21 day	501
	Lymphoma	R-Gemcitabine (1000mg/m ²) Oxaliplatin Therapy - 14 day	506
riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-G)		441	
Gemtuzumab ozog	Leukaemia/BMT	Gemtuzumab ozogamicin in combination with DAUNOrubicin anc	612
Goserelin	Genitourinary	Goserelin 10.8mg-12 Weekly Therapy	477
		Goserelin 3.6mg Therapy- 4 weeks	478
Ibrutinib	Leukaemia/BMT	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)	296
	Lymphoma	Ibrutinib Therapy (Mantle Cell Lymphoma)	297
Idarubicin	Leukaemia/BMT	FLAG:Ida 8mg/m ² Therapy	362
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Idelalisib	Leukaemia/BMT	Idelalisib and Ofatumumab Therapy	390
		Idelalisib and riTUXimab Therapy	389
	Lymphoma	Idelalisib Monotherapy	291
Ifosfamide	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
	Lymphoma	((R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		SMILE Therapy (NK or T-cell lymphoma)	407
	Brentuximab vedotin and ICE Therapy	528	
Imatinib	Sarcoma	Imatinib Therapy-GIST	335
Inotuzumab ozogamicin	Leukaemia/BMT	Inotuzumab ozogamicin Monotherapy	537
Ipilimumab	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Skin/Melanoma	Ipilimumab Monotherapy	105
		Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431
Irinotecan	Gastrointestinal	Aflibercept-14 days	238
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOXIRI Therapy	555
		Irinotecan Monotherapy - 21 days	213
		Modified FOLFIRINOX Therapy	515
Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448		

Irinotecan	Gastrointestinal	Irinotecan 150mg/m2 Monotherapy - 28 days	654
Isotretinoin	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
Ixazomib	Myeloma	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
Lapatinib	Breast	Lapatinib and Capecitabine	217
L-Asparaginase	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
Lenalidomide	Myeloma	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
		Lenalidomide 25mg and Dexamethasone Therapy - 28 day	218
		Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamet	405
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 2	643
Lenvatinib	Gastrointestinal	Lenvatinib -HCC Therapy	644
Lenvatinib	Head & Neck	Lenvatinib -DTC Therapy	295
Letrozole	Breast	Letrozole Monotherapy	371
Leuprorelin	Genitourinary	Leuprorelin 3.75mg Therapy-28 day	494
		Leuprorelin 30mg Therapy- 24 weeks	493
		Leuprorelin 45mg Therapy- 24 week	491
		Leuprorelin 7.5mg Therapy- 28 day	490
		Leuprorelin 11.25mg Therapy- 12 weeks	492
Leuprorelin	Genitourinary	Leuprorelin 22.5mg Therapy- 12 weeks	479
Lomustine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 day:	658
	Lymphoma	LEAM Autologous Transplant Conditioning Protocol	468
Lorlatinib	Lung	Lorlatinib therapy	570
Melphalan	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
		LEAM Autologous Transplant Conditioning Protocol	468
	Myeloma	Bortezomib , Melphalan and Prednisolone	275
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625
Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-		638	
MESNA	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
	Lymphoma and M	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438
Methotrexate	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Gynaecology	EMA/CO Therapy	248
		Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264

Methotrexate	Gynaecology	Intrathecal Methotrexate for CNS Prophylaxis in GTN	249
		Methotrexate 8 day Charing Cross Regimen	246
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and Cisplatin (60mg/m2) Therapy	463
		VinBLAStine and Methotrexate Therapy	554
	Lymphoma	High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRix) therapy	508
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		ritUXimab-HyperCVAD Therapy (MCL) – Part A	466
		SMILE Therapy (NK or T-cell lymphoma)	407
		ritUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper C	467
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatche	629
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatche	630
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
		Busulfan/Cyclophosphamide MAC-MUD	639
Busulfan/Cyclophosphamide MAC-SIB		641	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched		662	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched	663		
Methylprednisolone	Lymphoma	(R*)- ESHAP Therapy	394
Midostaurin	Leukaemia	Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
Mifamurtide	Sarcoma	Mifamurtide	100
mitoMYcin	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
Nab-PACLitaxel (Abraxane®)	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	230
	Gastrointestinal	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day	256
Nindetanib	Lung	Nindetanib Therapy	372
Niraparib	Gynaecology	Niraparib Monotherapy	571
Nivolumab	Genitourinary	Nivolulmab Monotherapy	349
	Head & Neck	Nivolulmab Monotherapy	349
	Skin/Melanoma	Nivolulmab Monotherapy	349
	Lymphoma	Nivolulmab Monotherapy	349
Nivolumab	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Head & Neck	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Lung	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Skin/Melanoma	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab 3mg/kg Monotherapy	573
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431
	Lymphoma	Nivolumab Monotherapy 240mg-14 day	483
Nivolumab Monotherapy 480mg-28day		484	
Obinutuzumab	Leukaemia/BMT	Obinutuzumab and Chlorambucil Therapy	286
	Lymphoma	Obinutuzumab and Bendamustine Therapy-28 day cycle	424
		Obinutuzumab and CHOP Therapy – 21 day	549

Obinutuzumab	Lymphoma	obinutuzumab and CVP therapy -21 days	550		
		Obinutuzumab Maintenance Therapy -56 day	425		
Ofatumumab	Leukaemia/BMT	Idelalisib and Ofatumumab Therapy	390		
Olaparib	Gynaecology	Olaparib (Tablet) Monotherapy	588		
		Olaparib (Capsule) Monotherapy	341		
Osimertinib	Lung	Osimertinib Monotherapy	353		
Oxaliplatin	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446		
		Capecitabine/Oxaliplatin (XELOX) Therapy	321		
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429		
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239		
		FLOT Therapy-14 day	344		
		FLOX Therapy	486		
		FOLFIRINOX Therapy	329		
		FOLFOX-4 Therapy-14 day	210		
		FOLFOXIRI Therapy	555		
		Modified FOLFIRINOX Therapy	515		
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509		
		Modified FOLFOX-6 Therapy-14 day	209		
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447		
		R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day	506		
		PACLitaxel	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
				Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485				
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316				
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433				
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260				
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432				
PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512				
Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507				
PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226				
Gastrointestinal	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621		
	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks		422		
	PACLitaxel Monotherapy 80mg/m2 7day		226		
Genitourinary	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621		
	TICE -Autologous Conditioning Germ Cell Tumour Regimen		437		
	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day		226		
Gynaecology	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621		
	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy		308		
			CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303	

PACLitaxel	Gynaecology	PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175r	620
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	676
	Lung	CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy	309
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
Palbociclib	Breast	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		Palbociclib Therapy-28 day	414
Panitumumab	Gastrointestinal	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		Panitumumab 6mg/kg Therapy	225
Pazopanib	Genitourinary	Pazopanib Therapy	445
	Sarcoma	Pazopanib Therapy	445
Pegylated Liposomal DOXOrubicin (CAELYX)	Breast	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX)® 28 days	205
		Gynaecology	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX)® 28 days
	Sarcoma	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/r	624
		Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX)® 21 days	462
Pembrolizumab	Genitourinary	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg and Axitinib Therapy	583
	Lung	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
	Skin/Melanoma	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 2mg/kg Therapy	347
		Pembrolizumab 400mg Monotherapy	558
	Lymphoma	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
	PEMEtrexed	Lung	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy
Pembrolizumab, PEMEtrexed and CISplatin Therapy			569
PEMEtrexed and CARBOplatin Therapy			318
PEMEtrexed and CISplatin Therapy			317
PEMEtrexed Monotherapy			222
Pertuzumab	Breast	Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
Pixantrone	Lymphoma	Pixantrone Therapy	255
Plerixafor	Lymphoma, Myel	Plerixafor and G-CSF Therapy	536
Pomalidomide	Myeloma	Pomalidomide and Dexamethasone	245
Ponatinib	Leukaemia/BMT	Ponatinib Therapy	302
Procarbazine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379

Procarbazine	Neuro-oncology	Procarbazine, Lomustine and VinCRiStine (PCV) Therapy – 56 day:	658	
	Lymphoma	Escalated Dose BEACOPP 21 day Therapy	354	
Radium 223	Genitourinary	Radium 223 Therapy	257	
Regorafenib	Gastrointestinal	Regorafenib Monotherapy	244	
Ribociclib	Breast	Ribociclib Therapy-28 day	525	
riTUXimab	Leukaemia/BMT	Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241	
		Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410	
		Idelalisib and riTUXimab Therapy	389	
		Venetoclax and Rituximab therapy	575	
	Lymphoma	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRiStine and Prednisolone (*R)-CHOP Therapy– 14 days	409
			(*riTUXimab), Cyclophosphamide VinCRiStine and Prednisolone (*R)-CVP) Therapy– 21 days	293
			(R*)-CHOP – 21 days	307
			(R**)- miniCHOP Therapy – 21 days	436
			(R**)-DHAP Therapy	395
			(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
			Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532
			Dose Adjusted R-EPOCH Therapy	355
			High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
			Nordic Therapy	393
			R-CEOP Therapy – 21 days	510
			R-CODOX-M Therapy (Patients greater than 65 years)	403
			R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
			R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506
			riTUXimab 375 mg/m2 Combination Therapy-21 day	542
			RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day	543
			RiTUXimab 375 mg/m2 Maintenance Therapy-84 day	540
			RiTUXimab 375 mg/m2 Therapy-7 day	541
			RiTUXimab 375mg/m2 Therapy-Follicular Lymphoma	208
			riTUXimab and Bendamustine Therapy	345
			riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
			R-IVAC Therapy (Patients greater than 65 years)	404
			R-IVAC Therapy (Patients less than or equal to 65 years)	399
			riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper C	467
			(R*)- ESHAP Therapy	394
			riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-Gl	441
			RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day	599
	RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day	600		
	riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRiStine anc	667		
Dose Adjusted R (S/C)-EPOCH Therapy	672			
Leukaemia/BMT,	Leukaemia/BMT,	Cladribine 5 day and riTUXimab Therapy	531	
		Cladribine Weekly and riTUXimab Therapy	534	
Ruxolitinib	Leukaemia/BMT	Ruxolitinib Monotherapy	229	
Siltuximab	Lymphoma	Siltuximab Monotherapy	277	
Sorafenib	Gastrointestinal	Sorafenib Therapy	294	
	Genitourinary	Sorafenib Therapy	294	
	Head & Neck	Sorafenib Therapy	294	
Sunitinib	Genitourinary	Sunitinib 50mg Therapy	325	

Sunitinib	Sarcoma	Sunitinib 50mg Therapy	325
	Neuroendocrine	Sunitinib 37.5mg Therapy	327
Talazoparib	Breast	Talazoparib Therapy	605
Tamoxifen	Breast	Tamoxifen Monotherapy	253
Temozolomide	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505
	Neuro-oncology	Temozolomide Recurrent Therapy	342
		Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years	461
		Temozolomide with RT and Adjuvant Therapy	334
Temsirolimus	Genitourinary	Temsirolimus Monotherapy	326
Teysuno	Gastrointestinal	CISplatin and Teysuno-28 day cycle	235
Thalidomide	Myeloma	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
Thiotepa	Lymphoma	High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRix) therapy	508
Tipracil	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Tisagenlecleucel	CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL	686
		Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL	687
Tivozanib	Genitourinary	Tivozanib Therapy	564
Topotecan	Gynaecology	Topotecan Monotherapy-5 day	311
		Topotecan Monotherapy-Weekly	312
	Lung	Topotecan Monotherapy-5 day	311
		Topotecan Oral Monotherapy	587
Trabectedin	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
	Sarcoma	Trabectedin Monotherapy	374
Trametinib	Skin/Melanoma	Trametinib and Dabrafenib Therapy	415
Trastuzumab Emtansine (Kadcyla®)	Breast	Trastuzumab Emtansine (Kadcyla®) - 21 days	206
Trastuzumab IV	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		Trastuzumab (IV) Monotherapy 21 days	200
		Trastuzumab (IV) Monotherapy 7 days	201
		Gastrointestinal	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days
Trastuzumab SC	Breast	Trastuzumab SC 21 days-Early Breast Cancer	285
		Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	272
Trastuzumab	Breast	DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
Tretinoin (ATRA)	Leukaemia/BMT	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357

Tretinoin (ATRA)	Leukaemia/BMT	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Trifluridine	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Triptorelin	Genitourinary	Triptorelin 11.25mg Therapy- 12 weeks	480
		Triptorelin 22.6mg Therapy- 24 weeks	488
		Triptorelin 3mg Therapy- 28 day	489
Vandetanib	Head & Neck	Vandetanib Monotherapy	242
Vemurafenib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
		Vemurafenib Monotherapy	102
Venetoclax	Leukaemia/BMT	Venetoclax Monotherapy	400
Venetoxlax	Leukaemia/BMT	Venetoclax and Rituximab therapy	575
Vinblastine	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Sarcoma	VinBLAStine and Methotrexate Therapy	554
	Lymphoma	ABVD Therapy	290
VinCRIStine	Gynaecology	EMA/CO Therapy	248
	Neuro-oncology	Procarbazine Lomustine and VinCRIStine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 day:	658
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**) - miniCHOP Therapy – 21 days	436
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		Obinutuzumab and CHOP Therapy – 21 day	549
		obinutuzumab and CVP therapy -21 days	550
	R-CEOP Therapy – 21 days	510	
	R-CODOX-M Therapy (Patients greater than 65 years)	403	
	R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
	riTUXimab-HyperCVAD Therapy (MCL) – Part A	466	
	Cyclophosphamide, DOXOrubicin, vinCRIStine and prednisoLONE (riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRIStine and	307.1	
	Dose Adjusted R (S/C)-EPOCH Therapy	667	
	672		
Vinorelbine	Lung	CARBOplatin and vinORELbine Therapy-21 Day	614
Vinorelbine IV	Breast	Intravenous Vinorelbine Monotherapy-21day	232
		Pertuzumab Trastuzumab and VinORELBine	526
	Gynaecology	Intravenous Vinorelbine Monotherapy-21day	232
	Lung	Intravenous Vinorelbine Monotherapy-21day	232
		Vinorelbine and CISplatin Therapy-21 days	339
	Vinorelbine and CISplatin Therapy-28 days	343	
Vinorelbine Oral	Breast	Oral Vinorelbine Monotherapy-7days	259
	Lung	Oral Vinorelbine Monotherapy-7days	259
Vismodegib	Skin/Melanoma	Vismodegib Monotherapy	236
Vyxeos liposomal®	Leukaemia/BMT	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction The	613
		Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation	618
Zoledronic acid	Breast	Zoledronic acid monotherapy	545